Jeffrey R. Marks
Jeffrey R. Marks
Verified email at
Cited by
Cited by
Comprehensive molecular portraits of human breast tumours
Cancer Genome Atlas Network
Nature 490 (7418), 61, 2012
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
AH Bild, G Yao, JT Chang, Q Wang, A Potti, D Chasse, MB Joshi, ...
Nature 439 (7074), 353-357, 2006
Predicting the clinical status of human breast cancer by using gene expression profiles
M West, C Blanchette, H Dressman, E Huang, S Ishida, R Spang, H Zuzan, ...
Proceedings of the National Academy of Sciences 98 (20), 11462-11467, 2001
BRCA1 mutations in primary breast and ovarian carcinomas
PA Futreal, Q Liu, D Shattuck-Eidens, C Cochran, K Harshman, ...
Science 266 (5182), 120-122, 1994
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
Comprehensive molecular portraits of invasive lobular breast cancer
G Ciriello, ML Gatza, AH Beck, MD Wilkerson, SK Rhie, A Pastore, ...
Cell 163 (2), 506-519, 2015
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
CK Anders, DS Hsu, G Broadwater, CR Acharya, JA Foekens, Y Zhang, ...
Journal of clinical oncology 26 (20), 3324-3330, 2008
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics
J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ...
Cell 173 (2), 400-416. e11, 2018
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
Genomic signatures to guide the use of chemotherapeutics
A Potti, HK Dressman, A Bild, RF Riedel, G Chan, R Sayer, J Cragun, ...
Nature medicine 12 (11), 1294-1300, 2006
Overexpression and mutation of p53 in epithelial ovarian cancer
JR Marks, AM Davidoff, BJ Kerns, PA Humphrey, JC Pence, RK Dodge, ...
Cancer research 51 (11), 2979-2984, 1991
Compromised HOXA5 function can limit p53 expression in human breast tumours
V Raman, SA Martensen, D Reisman, E Evron, WF Odenwald, E Jaffee, ...
Nature 405 (6789), 974-978, 2000
High frequency of hypermethylation at the 14-3-3 σ locus leads to gene silencing in breast cancer
AT Ferguson, E Evron, CB Umbricht, TK Pandita, TA Chan, H Hermeking, ...
Proceedings of the National Academy of Sciences 97 (11), 6049-6054, 2000
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells
T Baba, PA Convery, N Matsumura, RS Whitaker, E Kondoh, T Perry, ...
Oncogene 28 (2), 209-218, 2009
Artificial neural networks improve the accuracy of cancer survival prediction
HB Burke, PH Goodman, DB Rosen, DE Henson, JN Weinstein, ...
Cancer 79 (4), 857-862, 1997
BRCA2 mutations in primary breast and ovarian cancers
JM Lancaster, R Wooster, J Mangion, CM Phelan, C Cochran, C Gumbs, ...
Nature genetics 13 (2), 238-240, 1996
Machine learning identifies stemness features associated with oncogenic dedifferentiation
TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ...
Cell 173 (2), 338-354. e15, 2018
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.
AM Davidoff, JD Iglehart, JR Marks
Proceedings of the National Academy of Sciences 89 (8), 3439-3442, 1992
The system can't perform the operation now. Try again later.
Articles 1–20